NCT07055009 Multi-centred Clinico-genetic Study of Actinic Prurigo in Thailand
| NCT ID | NCT07055009 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chulalongkorn University |
| Condition | Actinic Prurigo |
| Study Type | OBSERVATIONAL |
| Enrollment | 47 participants |
| Start Date | 2025-03-30 |
| Primary Completion | 2026-05-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 47 participants in total. It began in 2025-03-30 with a primary completion date of 2026-05-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This research project investigates the clinical and genetic associations of Actinic Prurigo (AP) in the Thai population. As a rare chronic photodermatosis, AP has been observed to occur more frequently in individuals with certain genetic predispositions, particularly specific Human Leukocyte Antigen (HLA) types. Previous studies have suggested variations in clinical presentation and HLA allele distributions between Asian and Western populations. The primary aim is to explore the relationship between clinical manifestations of AP and genetic profiles, including HLA typing, among Thai individuals. Additionally, the study seeks to examine whether different HLA types are associated with varying responses to treatment. The study design is a cross-sectional comparative study, involving both AP patients and age-matched healthy controls. Given the rarity of the condition, patient recruitment will be conducted across four collaborating institutions: King Chulalongkorn Memorial Hospital Siriraj Hospital Institute of Dermatology
Eligibility Criteria
Inclusion Criteria: * Thai ethnicity * Diagnosed with Actinic Prurigo (AP) according to the diagnostic criteria defined for this study * Mentally competent, able to communicate, and able to read Thai. * Participants receiving Thalidomide treatment must use two simultaneous methods of contraception, starting at least 4 weeks prior to initiating the medication and continuing throughout the treatment period and for at least 4 weeks after discontinuation. Exclusion Criteria: * History and physical examination findings suggestive of other photodermatoses such as Lupus erythematosus, Porphyria, or Polymorphous Light Eruption, among others. * Elevated Epstein-Barr Virus (EBV) viral load detected in blood testing (EBV viral load will be tested in all participants). * Low Minimal Erythema Dose (MED) to UVB radiation as the only abnormal finding.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07055009 clinical trial?
This trial is open to participants of all sexes, studying Actinic Prurigo. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07055009 currently recruiting?
Yes, NCT07055009 is actively recruiting participants. Contact the research team at einapak.b@chula.ac.th for enrollment information.
Where is the NCT07055009 trial being conducted?
This trial is being conducted at Bangkok, Thailand.
Who is sponsoring the NCT07055009 clinical trial?
NCT07055009 is sponsored by Chulalongkorn University. The trial plans to enroll 47 participants.